create a website

The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. (2020). Blankart, Katharina ; Stargardt, Tom.
In: Health Economics.
RePEc:wly:hlthec:v:29:y:2020:i:s1:p:63-82.

Full description at Econpapers || Download paper

Cited: 3

Citations received by this document

Cites: 57

References cited by this document

Cocites: 50

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. Does health technology assessment compromise access to pharmaceuticals?. (2023). Stargardt, Tom ; Bussgen, Melanie.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:24:y:2023:i:3:d:10.1007_s10198-022-01484-4.

    Full description at Econpapers || Download paper

  2. Technology adoption by primary care physicians. (2022). Ma, Ching-to ; Iversen, Tor.
    In: Health Economics.
    RePEc:wly:hlthec:v:31:y:2022:i:3:p:443-465.

    Full description at Econpapers || Download paper

  3. Innovation, aging, and health care: Unraveling “silver” from “red” herrings?. (2020). LEVAGGI, ROSELLA ; Costa-Font, Joan ; Costafont, Joan.
    In: Health Economics.
    RePEc:wly:hlthec:v:29:y:2020:i:s1:p:3-7.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Abadie, A., & Cattaneo, M. D. (2018). Econometric methods for program evaluation. Annual Review of Economics, 10(1), 465–503. https://doi.org/10.1146/annurev-economics-080217-053402.
    Paper not yet in RePEc: Add citation now

  2. Agarwal, R., & Bayus, B. L. (2002). The market evolution and sales takeoff of product innovations. Management Science, 48(8), 1024–1041. https://doi.org/10.1287/mnsc.48.8.1024.167.

  3. Austin, P. C., & Stuart, E. A. (2015). Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in Medicine, 34(28), 3661–3679. https://doi.org/10.1002/sim.6607.
    Paper not yet in RePEc: Add citation now

  4. Azoulay, P. (2002). Do pharmaceutical sales respond to scientific evidence? Journal of Economics and Management Strategy, 11(4), 551–594. https://doi.org/10.1111/j.1430-9134.2002.00551.x.

  5. Berndt, E. R., Gibbons, R. S., Kolotilin, A., & Taub, A. L. (2015). The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics. Journal of Health Economics, 40, 26–39. https://doi.org/10.1016/j.jhealeco.2014.11.003.

  6. Berndt, E. R., Pindyck, R. S., & Azoulay, P. (2000). Consumption externalities and diffusion in pharmaceutical markets: Antiulcer drugs (Working Paper No. 7772). National Bureau of Economic Research. Retrieved from http://www.nber.org/papers/w7772.

  7. Blankart, K., & Stargardt, T. (2017). DFG FI 1950/1‐1‐STA 1311/1‐1 Early benefit assessment of innovative pharmaceuticals according to AMNOG in Germany: Empirical analysis of the decision‐making process. https://doi.org/10.13140/RG.2.2.18391.16809.
    Paper not yet in RePEc: Add citation now

  8. Bradford, W. D., & Kleit, A. N. (2015). Impact of FDA actions, DTCA, and public information on the market for pain medication. Health Economics, 24(7), 859–875. https://doi.org/10.1002/hec.3067.

  9. Brekke, K. R., Canta, C., & Straume, O. R. (2016). Reference pricing with endogenous generic entry. Journal of Health Economics, 50, 312–329. https://doi.org/10.1016/j.jhealeco.2016.04.003.

  10. Chandra, A., & Skinner, J. (2012). Technology growth and expenditure growth in health care. Journal of Economic Literature, 50(3), 645–680. https://doi.org/10.1257/jel.50.3.645.

  11. Ching, A. (2010). Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. International Journal of Industrial Organization, 28(6), 619–638. https://doi.org/10.1016/j.ijindorg.2010.02.004.

  12. Ciani, O., & Jommi, C. (2014). The role of health technology assessment bodies in shaping drug development. Drug Design, Development and Therapy, 8, 2273–2281. https://doi.org/10.2147/DDDT.S49935.
    Paper not yet in RePEc: Add citation now

  13. Corbacho, B., Drummond, M., Santos, R., Jones, E., Borràs, J. M., Mestre‐Ferrandiz, J., … Prat, A. (2020). Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries. The European Journal of Health Economics., 21, 621–634. https://doi.org/10.1007/s10198-020-01160-5.

  14. Coscelli, A. (2003). The importance of doctors' and patients' preferences in the prescription decision. The Journal of Industrial Economics, 48(3), 349–369. https://doi.org/10.1111/1467-6451.00127.
    Paper not yet in RePEc: Add citation now

  15. Coscelli, A., & Shum, M. (2004). An empirical model of learning and patient spillovers in new drug entry. Journal of Econometrics, 122(2), 213–246. https://doi.org/10.1016/j.jeconom.2003.09.002.

  16. Danzon, P. M., & Chao, L.‐W. (2000). Cross‐national price differences for pharmaceuticals: How large, and why? Journal of Health Economics, 19(2), 159–195. https://doi.org/10.1016/S0167-6296(99)00039-9.

  17. de Frutos, M.‐A., Ornaghi, C., & Siotis, G. (2013). Competition in the pharmaceutical industry: How do quality differences shape advertising strategies? Journal of Health Economics, 32(1), 268–285. https://doi.org/10.1016/j.jhealeco.2012.07.006.

  18. Dorsey, E., Rabbani, A., Gallagher, S. A., Conti, R. M., & Alexander, G. (2010). Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine, 170(1), 96–103. https://doi.org/10.1001/archinternmed.2009.456.
    Paper not yet in RePEc: Add citation now
  19. Dranove, D. (2012). Health care markets, regulators, and certifiers. In A. J. Culyer, & M. V. Pauly (Eds.), Handbook of health economics (1st ed.). Amsterdam: Elsevier.
    Paper not yet in RePEc: Add citation now
  20. European Pharmaceutical Market Research Association. (2016). EphMRA Anatomical Classification. EphMRA. Retrieved from http://www.ephmra.org/Classification.
    Paper not yet in RePEc: Add citation now
  21. Federal Joint Committee. (2015, August 3). (Frühe) Nutzenbewertung nach § 35a SGB V ‐ Gemeinsamer Bundesausschuss. Retrieved from https://www.g-ba.de/informationen/nutzenbewertung/.
    Paper not yet in RePEc: Add citation now

  22. Fischer, K. E., & Stargardt, T. (2014). Early benefit assessment of pharmaceuticals in Germany manufacturers' expectations versus the Federal Joint Committee's decisions. Medical Decision Making, 34(8), 1030–1047. https://doi.org/10.1177/0272989X14546377.

  23. Fischer, K. E., Koch, T., Kostev, K., & Stargardt, T. (2018). The impact of physician‐level drug budgets on prescribing behavior. The European Journal of Health Economics, 19(2), 213–222. https://doi.org/10.1007/s10198-017-0875-9.

  24. Gallan, A. S. (2004). Factors that influence physicians' prescribing of pharmaceuticals: A literature review. Journal of Pharmaceutical Marketing & Management, 16(4), 3–46. https://doi.org/10.3109/J058v16n04_02.
    Paper not yet in RePEc: Add citation now
  25. German Federal Institute for Drugs and Medical Devices. (2015, August 3). BfArM ‐ UAW‐Datenbank [side effects database]. Retrieved from http://nebenwirkung.bfarm.de/.
    Paper not yet in RePEc: Add citation now

  26. Granlund, D. (2010). Price and welfare effects of a pharmaceutical substitution reform. Journal of Health Economics, 29(6), 856–865. https://doi.org/10.1016/j.jhealeco.2010.08.003.

  27. Hainmueller, J. (2012). Entropy balancing for causal effects: A multivariate reweighting method to produce balanced samples in observational studies. Political Analysis, 20(1), 25–46. https://doi.org/10.1093/pan/mpr025.

  28. Huber, C. A., Szucs, T. D., Rapold, R., & Reich, O. (2013). Identifying patients with chronic conditions using pharmacy data in Switzerland: An updated mapping approach to the classification of medications. BMC Public Health, 13(1), 1030. https://doi.org/10.1186/1471-2458-13-1030.
    Paper not yet in RePEc: Add citation now
  29. Hwang, T. J., Kesselheim, A. S., & Sarpatwari, A. (2017). Value‐based pricing and state reform of prescription drug costs. JAMA, 318(7), 609–610. https://doi.org/10.1001/jama.2017.8255.
    Paper not yet in RePEc: Add citation now

  30. Kalra, A., Li, S., & Zhang, W. (2011). Understanding responses to contradictory information about products. Marketing Science, 30(6), 1098–1114. https://doi.org/10.1287/mksc.1110.0671.

  31. Kremer, S. T. M., Bijmolt, T. H. A., Leeflang, P. S. H., & Wieringa, J. E. (2008). Generalizations on the effectiveness of pharmaceutical promotional expenditures. International Journal of Research in Marketing, 25(4), 234–246. https://doi.org/10.1016/j.ijresmar.2008.08.001.

  32. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA, 287(17), 2215–2220. https://doi.org/10.1001/jama.287.17.2215.
    Paper not yet in RePEc: Add citation now
  33. Lauenroth, V. D., & Stargardt, T. (2017). Pharmaceutical pricing in Germany: How is value determined within the scope of AMNOG? Value in Health, 20, 927–935. https://doi.org/10.1016/j.jval.2017.04.006.
    Paper not yet in RePEc: Add citation now
  34. Lee, H., Smith, K. G., & Grimm, C. M. (2003). The effect of new product radicality and scope on the extent and speed of innovation diffusion. Journal of Management, 29(5), 753–768. https://doi.org/10.1016/S0149-2063_03_00034-5.
    Paper not yet in RePEc: Add citation now
  35. Libby, A. M., Brent, D. A., Morrato, E. H., Orton, H. D., Allen, R., & Valuck, R. J. (2007). Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. American Journal of Psychiatry, 164, 884–891. https://doi.org/10.1176/ajp.2007.164.6.884.
    Paper not yet in RePEc: Add citation now
  36. Liu, Q., & Gupta, S. (2012). A micro‐level diffusion model for new drug adoption. Journal of Product Innovation Management, 29(3), 372–384. https://doi.org/10.1111/j.1540-5885.2012.00912.x.
    Paper not yet in RePEc: Add citation now
  37. Luce, B. R., Drummond, M., Jonsson, B., Neumann, P. J., Schwartz, J. S., Siebert, U., & Sullivan, S. D. (2010). EBM, HTA, and CER: Clearing the confusion. Milbank Quarterly, 88, 256–276. https://doi.org/10.1111/j.1468-0009.2010.00598.x.
    Paper not yet in RePEc: Add citation now
  38. Miller, K. (2016, June 13). Creating a conceptual framework and index to measure pharmaceutical innovation. 6th Biennial Conference of the American Society of Health Economists. Retrieved from https://ashecon.confex.com/ashecon/2016/webprogram/Paper4872.html.
    Paper not yet in RePEc: Add citation now
  39. Neumann, P. J., & Cohen, J. T. (2015). Measuring the value of prescription drugs. New England Journal of Medicine, 373, 2595–2597. https://doi.org/10.1056/NEJMp1512009.
    Paper not yet in RePEc: Add citation now
  40. Rogers, E. M. (2003). Diffusion of innovations (5th ed.). New York: Free Press.
    Paper not yet in RePEc: Add citation now

  41. Rogowski, W. (2013). An economic theory of the fourth hurdle. Health Economics, 22(5), 600–610. https://doi.org/10.1002/hec.2830.

  42. Schlette, S., & Hess, R. (2013). Early benefit assessment for pharmaceuticals in Germany: Lessons for policymakers. The Commonwealth Fund, 29, 1–9.
    Paper not yet in RePEc: Add citation now
  43. Sculpher, M., & Claxton, K. (2005). Establishing the cost‐effectiveness of new pharmaceuticals under conditions of uncertainty—When is there sufficient evidence? Value in Health, 8(4), 433–446. https://doi.org/10.1111/j.1524-4733.2005.00033.x.
    Paper not yet in RePEc: Add citation now

  44. Serra‐Sastre, V., & McGuire, A. (2013). Information and diffusion of new prescription drugs. Applied Economics, 45(15), 2049–2057. https://doi.org/10.1080/00036846.2011.648321.

  45. Sorenson, C., & Chalkidou, K. (2012). Reflections on the evolution of health technology assessment in Europe. Health Economics, Policy, and Law, 7(1), 25–45. https://doi.org/10.1017/S1744133111000296.

  46. Sorescu, A., Chandy, R. K., & Prabhu, J. C. (2003). Sources and financial consequences of radical innovation: Insights from pharmaceuticals. Journal of Marketing, 67, 82–102.
    Paper not yet in RePEc: Add citation now
  47. Stern, A. D., Pietrulla, F., Herr, A., Kesselheim, A. S., & Sarpatwari, A. (2019). The impact of price regulation on the availability of new drugs in Germany. Health Affairs, 38(7), 1182–1187. https://doi.org/10.1377/hlthaff.2018.05142.
    Paper not yet in RePEc: Add citation now

  48. Stern, P., & Wright, M. (2016). The adoption of new prescription drugs is strongly associated with prior category prescribing rate. International Journal of Research in Marketing, 33, 220–224. https://doi.org/10.1016/j.ijresmar.2015.12.002.

  49. Stros, M., & Lee, N. (2015). Marketing dimensions in the prescription pharmaceutical industry: A systematic literature review. Journal of Strategic Marketing, 23(4), 318–336. https://doi.org/10.1080/0965254X.2014.931878.
    Paper not yet in RePEc: Add citation now
  50. Tamblyn, R., Mcleod, P., Hanley, J. A., Girard, N., & Hurley, J. (2003). Physician and practice characteristics associated with the early utilization of new prescription drugs. Medical Care, 41(8), 895–908. https://doi.org/10.1097/00005650-200308000-00004.
    Paper not yet in RePEc: Add citation now
  51. Taylor, R. S. (2004). Inclusion of cost effectiveness in licensing requirements of new drugs: The fourth hurdle. BMJ, 329(7472), 972–975. https://doi.org/10.1136/bmj.329.7472.972.
    Paper not yet in RePEc: Add citation now
  52. Text ‐ H.R.3590‐111th Congress (2009‐2010). (2010). Patient Protection and Affordable Care Act. Retrieved from https://www.congress.gov/bill/111th-congress/house-bill/3590/text.
    Paper not yet in RePEc: Add citation now
  53. Thompson, G. N., Estabrooks, C. A., & Degner, L. F. (2006). Clarifying the concepts in knowledge transfer: A literature review. Journal of Advanced Nursing, 53(6), 691–701. https://doi.org/10.1111/j.1365-2648.2006.03775.x.
    Paper not yet in RePEc: Add citation now

  54. Venkataraman, S., & Stremersch, S. (2007). The debate on influencing doctors' decisions: Are drug characteristics the missing link? Management Science, 53(11), 1688–1701. https://doi.org/10.1287/mnsc.1070.0718.

  55. Wagner, A. K., Chan, K. A., Dashevsky, I., Raebel, M. A., Andrade, S. E., Lafata, J. E., … Platt, R. (2006). FDA drug prescribing warnings: Is the black box half empty or half full? Pharmacoepidemiology and Drug Safety, 15(6), 369–386. https://doi.org/10.1002/pds.1193.
    Paper not yet in RePEc: Add citation now
  56. Weatherby, L. B., Nordstrom, B. L., Fife, D., & Walker, A. M. (2002). The impact of wording in “Dear doctor” letters and in black box labels. Clinical Pharmacology & Therapeutics, 72(6), 735–742. https://doi.org/10.1067/mcp.2002.129503.
    Paper not yet in RePEc: Add citation now
  57. Wieseler, B., McGauran, N., & Kaiser, T. (2019). New drugs: Where did we go wrong and what can we do better? BMJ, 366, l4340. https://doi.org/10.1136/bmj.l4340.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. Exploring the relationship between technological improvement and innovation diffusion: An empirical test. (2018). Woo, Jongroul ; Magee, Christopher L.
    In: Papers.
    RePEc:arx:papers:1704.03597.

    Full description at Econpapers || Download paper

  2. Tracking Windows of Opportunity along the Industry Development Trajectory. (2017). Najda-Janoszka, Marta.
    In: MPRA Paper.
    RePEc:pra:mprapa:83438.

    Full description at Econpapers || Download paper

  3. Strategic Entry and Potential Competition - Evidence from Compressed Gas Fuel Retail. (2017). Rovigatti, Gabriele ; Pozzi, Andrea ; Pavan, Giulia.
    In: EIEF Working Papers Series.
    RePEc:eie:wpaper:1709.

    Full description at Econpapers || Download paper

  4. Toward Technology-Sensitive Catching-Up Policies: Insights from Renewable Energy in China. (2017). Hansen, Teis ; Gosens, Jorrit ; Binz, Christian.
    In: World Development.
    RePEc:eee:wdevel:v:96:y:2017:i:c:p:418-437.

    Full description at Econpapers || Download paper

  5. Strategic Entry and Potential Competition: Evidence from Compressed Gas Fuel Retail. (2017). Rovigatti, Gabriele ; Pozzi, Andrea ; Pavan, Giulia.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:12113.

    Full description at Econpapers || Download paper

  6. Incubation of an industry: Heterogeneous knowledge bases and modes of value capture. (2017). Agarwal, Rajshree ; Moeen, Mahka.
    In: Strategic Management Journal.
    RePEc:bla:stratm:v:38:y:2017:i:3:p:566-587.

    Full description at Econpapers || Download paper

  7. Regional drivers of on-farm energy production in Bavaria. (2016). Duvelmeyer, Claudia ; Schaffer, Axel.
    In: Energy Policy.
    RePEc:eee:enepol:v:95:y:2016:i:c:p:361-369.

    Full description at Econpapers || Download paper

  8. Innovation ecosystems and the pace of substitution: Re-examining technology S-curves. (2016). Adner, Ron ; Kapoor, Rahul.
    In: Strategic Management Journal.
    RePEc:bla:stratm:v:37:y:2016:i:4:p:625-648.

    Full description at Econpapers || Download paper

  9. The demand-side dynamics of entrant heterogeneity. (2015). MANRAL, LALIT.
    In: Journal of Evolutionary Economics.
    RePEc:spr:joevec:v:25:y:2015:i:2:p:401-445.

    Full description at Econpapers || Download paper

  10. Knowledge Diffusion and Industry Growth: The Case of Japans Early Cotton Spinning Industry. (2015). Braguinsky, Serguey.
    In: ISER Discussion Paper.
    RePEc:dpr:wpaper:0939.

    Full description at Econpapers || Download paper

  11. Complementarities and competition: Unpacking the drivers of entrants technology choices in the solar photovoltaic industry. (2015). Kapoor, Rahul ; Furr, Nathan R..
    In: Strategic Management Journal.
    RePEc:bla:stratm:v:36:y:2015:i:3:p:416-436.

    Full description at Econpapers || Download paper

  12. Characteristics of technological base, pace of technological development, and growth of young technology-based firms. (2014). Tischler, Joachim .
    In: EconStor Preprints.
    RePEc:zbw:esprep:96156.

    Full description at Econpapers || Download paper

  13. Determinants of Patent Citations in Biotechnology: An Analysis of Patent Influence Across the Industrial and Organizational Boundaries. (2014). Rotolo, Daniele ; Albino, Vito ; Petruzzelli, Antonio Messeni.
    In: SPRU Working Paper Series.
    RePEc:sru:ssewps:2014-05.

    Full description at Econpapers || Download paper

  14. Marginal abatement cost curves and the optimal timing of mitigation measures. (2014). Vogt-Schilb, Adrien ; Hallegatte, Stephane.
    In: Post-Print.
    RePEc:hal:journl:hal-00916328.

    Full description at Econpapers || Download paper

  15. Additionality, common practice and incentive schemes for the uptake of innovations. (2014). Bruce, Sarah ; Woodhams, Felicity ; Southwell, Darren ; Barnes, Belinda.
    In: Technological Forecasting and Social Change.
    RePEc:eee:tefoso:v:89:y:2014:i:c:p:43-61.

    Full description at Econpapers || Download paper

  16. Knowledge sources of entrepreneurship: Firm formation by academic, user and employee innovators. (2014). Shah, Sonali K. ; Agarwal, Rajshree.
    In: Research Policy.
    RePEc:eee:respol:v:43:y:2014:i:7:p:1109-1133.

    Full description at Econpapers || Download paper

  17. The challenges of pre-launch forecasting of adoption time series for new durable products. (2014). Meeran, Sheik ; Goodwin, Paul ; Dyussekeneva, Karima .
    In: International Journal of Forecasting.
    RePEc:eee:intfor:v:30:y:2014:i:4:p:1082-1097.

    Full description at Econpapers || Download paper

  18. Marginal abatement cost curves and the optimal timing of mitigation measures. (2014). Vogt-Schilb, Adrien ; Hallegatte, Stephane.
    In: Energy Policy.
    RePEc:eee:enepol:v:66:y:2014:i:c:p:645-653.

    Full description at Econpapers || Download paper

  19. Licensing radical product innovations to speed up the diffusion. (2014). VIDAL-SANZ, JOSE ; Esteban-Bravo, Mercedes ; Avagyan, Vardan.
    In: European Journal of Operational Research.
    RePEc:eee:ejores:v:239:y:2014:i:2:p:542-555.

    Full description at Econpapers || Download paper

  20. What doesnt kill you makes you stronger: The evolution of competition and entry-order advantages in economically turbulent contexts. (2014). Vassolo, Roberto S. ; Mesquita, Luiz F. ; Garcia-Sanchez, Javier .
    In: Strategic Management Journal.
    RePEc:bla:stratm:v:35:y:2014:i:13:p:1972-1992.

    Full description at Econpapers || Download paper

  21. Review of Diffusion Research. (2013). Sandström, Ulf ; Sandstrom, Ulf ; Sriwannawit, Pranpreya .
    In: INDEK Working Paper Series.
    RePEc:hhs:kthind:2013_001.

    Full description at Econpapers || Download paper

  22. Marginal abatement cost curves and the optimal timing of mitigation measures. (2013). Hallegatte, Stephane ; Vogt-Schilb, Adrien.
    In: Working Papers.
    RePEc:hal:wpaper:hal-00916328.

    Full description at Econpapers || Download paper

  23. Marginal abatement cost curves and the optimal timing of mitigation measures. (2013). Vogt-Schilb, Adrien ; Hallegatte, Stephane.
    In: CIRED Working Papers.
    RePEc:hal:ciredw:hal-00916328.

    Full description at Econpapers || Download paper

  24. Marginal Abatement Cost Curves and the Optimal Timing of Mitigation Measures. (2013). Vogt-Schilb, Adrien ; Hallegatte, Stephane.
    In: Working Papers.
    RePEc:fem:femwpa:2013.89.

    Full description at Econpapers || Download paper

  25. Diffusion of mobile handset features: Analysis of turning points and stages. (2013). Smura, Timo ; Toyli, Juuso ; Riikonen, Antti ; Kivi, Antero .
    In: Telecommunications Policy.
    RePEc:eee:telpol:v:37:y:2013:i:6:p:563-572.

    Full description at Econpapers || Download paper

  26. Identifying critical mass in the global cellular telephony market. (2012). Kretschmer, Tobias ; Grajek, Michal.
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:30:y:2012:i:6:p:496-507.

    Full description at Econpapers || Download paper

  27. Entrepreneurship capital and technical efficiency : the role of new business / firms as a conduit of knowledge spillovers. (2011). Sotelsek, Daniel ; Laborda, Leopoldo ; Guasch, Jose Luis.
    In: Policy Research Working Paper Series.
    RePEc:wbk:wbrwps:5739.

    Full description at Econpapers || Download paper

  28. Detecting the impact of market factors on sales takeoff times of analog cellular telephones. (2011). Islam, Towhidul ; Meade, Nigel.
    In: Marketing Letters.
    RePEc:kap:mktlet:v:22:y:2011:i:2:p:197-212.

    Full description at Econpapers || Download paper

  29. Explaining returns on venture capital backed companies: Evidence from Belgium. (2011). Hübner, Georges ; Alperovych, Yan ; Hubner, Georges.
    In: Research in International Business and Finance.
    RePEc:eee:riibaf:v:25:y:2011:i:3:p:277-295.

    Full description at Econpapers || Download paper

  30. Contingency Factors and the Technology-Performance-Relationship in Start-ups. (2010). Walter, Sascha G. ; Schmidt, Arne .
    In: EconStor Preprints.
    RePEc:zbw:esprep:37082.

    Full description at Econpapers || Download paper

  31. Drivers of peak sales for pharmaceutical brands. (2010). Verhoef, Peter ; Leeflang, Peter ; Fischer, Marc.
    In: Quantitative Marketing and Economics (QME).
    RePEc:kap:qmktec:v:8:y:2010:i:4:p:429-460.

    Full description at Econpapers || Download paper

  32. Strategic Entry Before Demand Takes Off. (2010). Villas-Boas, J. Miguel ; Shen, Qiaowei.
    In: Management Science.
    RePEc:inm:ormnsc:v:56:y:2010:i:8:p:1259-1271.

    Full description at Econpapers || Download paper

  33. Academic spin-offs transfer speed--Analyzing the time from leaving university to venture. (2010). Müller, Kathrin ; Muller, Kathrin.
    In: Research Policy.
    RePEc:eee:respol:v:39:y:2010:i:2:p:189-199.

    Full description at Econpapers || Download paper

  34. Functional Regression: A New Model for Predicting Market Penetration of New Products. (2009). Tellis, Gerard J. ; James, Gareth M. ; Sood, Ashish.
    In: Marketing Science.
    RePEc:inm:ormksc:v:28:y:2009:i:1:p:36-51.

    Full description at Econpapers || Download paper

  35. —Innovations Origins: When, By Whom, and How Are Radical Innovations Developed?. (2009). Shacham, Rachel ; Golder, Peter N. ; Mitra, Debanjan.
    In: Marketing Science.
    RePEc:inm:ormksc:v:28:y:2009:i:1:p:166-179.

    Full description at Econpapers || Download paper

  36. Understanding the timing of fast-second entry and the relevance of capabilities in invention vs. commercialization. (2009). Lee, Gwendolyn K..
    In: Research Policy.
    RePEc:eee:respol:v:38:y:2009:i:1:p:86-95.

    Full description at Econpapers || Download paper

  37. Global Takeoff of New Products: Culture, Wealth, or Vanishing Differences?. (2008). Tellis, Gerard J. ; Chandrasekaran, Deepa.
    In: Marketing Science.
    RePEc:inm:ormksc:v:27:y:2008:i:5:p:844-860.

    Full description at Econpapers || Download paper

  38. —Using Stock Prices to Predict Market Events: Evidence on Sales Takeoff and Long-Term Firm Survival. (2008). Golder, Peter N. ; Markovitch, Dmitri G..
    In: Marketing Science.
    RePEc:inm:ormksc:v:27:y:2008:i:4:p:717-729.

    Full description at Econpapers || Download paper

  39. The effects of advertising, prices and distribution on market share volatility. (2008). Vakratsas, Demetrios.
    In: European Journal of Operational Research.
    RePEc:eee:ejores:v:187:y:2008:i:1:p:283-293.

    Full description at Econpapers || Download paper

  40. The Impact of Foreign Direct Investment On New Firm Survival in the UK: Evidence For Static v. Dynamic Industries. (2007). Hanley, Aoife ; Görg, Holger ; Burke, Andrew ; Gorg, Holger.
    In: Discussion Papers.
    RePEc:not:notgep:07/09.

    Full description at Econpapers || Download paper

  41. Churn, Baby, Churn: Strategic Dynamics Among Dominant and Fringe Firms in a Segmented Industry. (2007). de Figueiredo, John M. ; Silverman, Brian S..
    In: Management Science.
    RePEc:inm:ormnsc:v:53:y:2007:i:4:p:632-650.

    Full description at Econpapers || Download paper

  42. Market-level information and the diffusion of competing technologies: An exploratory analysis of the LAN industry. (2007). Wong, Veronica ; Theoharakis, Vasilis ; Vakratsas, Demetrios.
    In: Research Policy.
    RePEc:eee:respol:v:36:y:2007:i:5:p:742-757.

    Full description at Econpapers || Download paper

  43. Targeting and timing promotional activities: An agent-based model for the takeoff of new products. (2007). JAGER, W. ; Delre, S. A. ; Janssen, M. A. ; Bijmolt, T. H. A., .
    In: Journal of Business Research.
    RePEc:eee:jbrese:v:60:y:2007:i:8:p:826-835.

    Full description at Econpapers || Download paper

  44. Research on Innovation: A Review and Agenda for. (2006). Hauser, John ; Tellis, Gerard J. ; Griffin, Abbie.
    In: Marketing Science.
    RePEc:inm:ormksc:v:25:y:2006:i:6:p:687-717.

    Full description at Econpapers || Download paper

  45. Conceptualising the heterogeneity of research-based spin-offs: A multi-dimensional taxonomy. (2006). Mustar, Philippe ; Clarysse, Bart ; Moray, Nathalie ; Colombo, Massimo G. ; Renault, Marie ; Fontes, Margarida ; Piva, Evila ; Lockett, Andy.
    In: Research Policy.
    RePEc:eee:respol:v:35:y:2006:i:2:p:289-308.

    Full description at Econpapers || Download paper

  46. 50th Anniversary Article: Technological Innovation, Product Development, and Entrepreneurship in Management Science. (2004). Shane, Scott A. ; Ulrich, Karl T..
    In: Management Science.
    RePEc:inm:ormnsc:v:50:y:2004:i:2:p:133-144.

    Full description at Econpapers || Download paper

  47. Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test. (2004). Stremersch, Stefan ; van den Bulte, Christophe.
    In: Marketing Science.
    RePEc:inm:ormksc:v:23:y:2004:i:4:p:530-544.

    Full description at Econpapers || Download paper

  48. Editorial: Consulting, Research, and Consulting Research. (2004). Shugan, Steven M..
    In: Marketing Science.
    RePEc:inm:ormksc:v:23:y:2004:i:2:p:173-179.

    Full description at Econpapers || Download paper

  49. A Micromodel of New Product Adoption with Heterogeneous and Forward-Looking Consumers: Application to the Digital Camera Category. (2003). Chintagunta, Pradeep ; Song, Inseong .
    In: Quantitative Marketing and Economics (QME).
    RePEc:kap:qmktec:v:1:y:2003:i:4:p:371-407.

    Full description at Econpapers || Download paper

  50. Weathering Tight Economic Times: The Sales Evolution Of Consumer Durables Over The Business Cycle. (2003). Parker, P. M. ; Sarvary, M. ; Dekimpe, M. G. ; Deleersnyder, B..
    In: ERIM Report Series Research in Management.
    RePEc:ems:eureri:428.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2025-10-04 08:58:26 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated August, 3 2024. Contact: Jose Manuel Barrueco.